On Sep. 19, 2017, Aplagon Oy, a pharmaceutical discovery and development company based in Helsinki, Finland, entered into a development and commercialization agreement with Cadila Pharmaceuticals Sweden AB, for Aplagon s proprietary lead anti-platelet, anti-coagulant (APAC) product. APACs are loOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.